BBIO · BridgeBio Pharma, Inc.

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including: - By Month 1, numerically fewer cumulative cardiovascular events, including CVM or recurrent CVH, were observed with acoramidis compared to placebo - A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 - A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30 - Acoramidis is the first and only approved ATTR-CM treatment in the U.S., EU, UK, Switzerland, Japan, and Brazil that all have a label specifying near-complete stabilization (≥90%) PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Brazilian Health Regulatory Agency (ANVISA)

PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data in individuals with autosomal dominant hypocalcemia type 1 (ADH1) from CALIBRATE, its Phase 3 study of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) taking place in Prague, Czech Republic on May 9-12, 2026. The Company will also share an additional oral presentation, one poster, and one eposter at the meeting. Oral Presentations: Encaleret Restores Mineral Homeostasis in ADH1: Primary Results from the Phase 3 CALIBRATE Trial Presenter: Filomena Cetani, M.D., Ph.D., University of Pisa, IT Date & Time: Tuesday, May 12 at 11:50 am CEST Genetic Testing of Over 400 Individuals with Non-Surgical Hypoparathyroidism Shows Gain-of-Function CASR Variants as the Most Common

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today upcoming presentations, including one late-breaking oral presentation, of new data from the Phase 3 ATTRibute-CM study in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology (ESC-HF), taking place in Barcelona, Spain on May 9-12, 2026. Bayer, BridgeBio’s exclusive European licensing partner of acoramidis, will be presenting a late-breaking oral presentation on data from ATTRibute-CM related to acoramidis’ impact on the outcome of outpatient worsening heart failure. Acoramidis is approved as Attruby ® by the U.S. FDA and is approved as BEYONTTRA ® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the

PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its first quarter 2026 financial results and business update after the market closes on Thursday, May 7, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/ . A replay of the webcast will be available on the BridgeBio website for 30 days following the event. Participants may access the webcast by registering online using the following link, here . About BridgeBio Pharma, Inc. BridgeBio exists to develop transformative medicines for genetic conditions.

- New national campaign encourages recognition of ATTR-CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a biopharmaceutical company focused on developing medicines for genetic conditions, has teamed up with award-winning actor Morgan Freeman and Howard “H” White, a longtime basketball apparel marketing executive, cultural connector, and heart health advocate, to bring greater attention to ATTR-CM, a progressive heart disease that can be underrecognized and often mistaken for other forms of heart failure. 1 , 2 Don’t Pass On Your Heart Health encourages people to take persistent symptoms seriously, recognizing that earlier action can help support better long-term outcomes. Although ATTR-CM has historically been diagnosed more often in men, research suggests the need for broader awareness across

PALO ALTO, Calif., April 22, 2026 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on April 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 33 new employees in restricted stock units for an aggregate of 67,247 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on May 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and

- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) - Acoramidis mitigated the rise in NT-proBNP through Month 54 to an extent not seen in the era of disease modifying treatments - Early and continuous acoramidis treatment stabilized and maintained all measures of heart failure-related QOL scores (KCCQ-OS), which demonstrates that the improvement in duration and quality of life in patients with ATTR-CM by acoramidis is sustained PALO ALTO, Calif., March 30, 2026 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today presented long-term efficacy and safety data from the ATTRibute-CM open-label extension (OLE) trial, demonstrating sustained clinical benefit of acoramidis through Month 54 in patients with ATTR-CM. These data were presented at the American College of